ATE165511T1 - Behandlung von organtransplantatsabstossung - Google Patents

Behandlung von organtransplantatsabstossung

Info

Publication number: ATE165511T1
Authority: AT; Austria
Prior art keywords: treatment; organt; transplant rejection; fluoro; carboxylic acid
Prior art date: 1990-06-11

Application number

AT91910880T

Other languages

English (en)

Inventor

Neil Richard Ackerman

Bruce Donald Jaffee

Original Assignee

Du Pont Merck Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-11

Filing date

1991-06-05

Publication date

1998-05-15

1991-06-05 Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma

1998-05-15 Application granted granted Critical

1998-05-15 Publication of ATE165511T1 publication Critical patent/ATE165511T1/de

Links

206010052779 Transplant rejections Diseases 0.000 title 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 abstract 1
208000037976 chronic inflammation Diseases 0.000 abstract 1
208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
208000024908 graft versus host disease Diseases 0.000 abstract 1
229940125721 immunosuppressive agent Drugs 0.000 abstract 1
239000003018 immunosuppressive agent Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
VQMSRUREDGBWKT-UHFFFAOYSA-N quinoline-4-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=CC=NC2=C1 VQMSRUREDGBWKT-UHFFFAOYSA-N 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT91910880T 1990-06-11 1991-06-05 Behandlung von organtransplantatsabstossung ATE165511T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/535,672 US5204329A (en)	1990-06-11	1990-06-11	Treatment of organ transplantation rejection

Publications (1)

Publication Number	Publication Date
ATE165511T1 true ATE165511T1 (de)	1998-05-15

Family

ID=24135268

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT91910880T ATE165511T1 (de)	1990-06-11	1991-06-05	Behandlung von organtransplantatsabstossung

Country Status (14)

Country	Link
US (1)	US5204329A (de)
EP (1)	EP0537191B1 (de)
JP (1)	JPH05507697A (de)
KR (1)	KR930700107A (de)
AT (1)	ATE165511T1 (de)
AU (1)	AU664354B2 (de)
CA (1)	CA2085002A1 (de)
DE (1)	DE69129332T2 (de)
DK (1)	DK0537191T3 (de)
ES (1)	ES2114888T3 (de)
IE (1)	IE911962A1 (de)
IL (1)	IL98425A (de)
WO (1)	WO1991019498A1 (de)
ZA (1)	ZA914456B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06116151A (ja) *	1991-08-06	1994-04-26	Asahi Chem Ind Co Ltd	増殖性皮膚疾患治療用組成物
US6270766B1 (en)	1992-10-08	2001-08-07	The Kennedy Institute Of Rheumatology	Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) *	1992-10-08	2004-08-03	The Kennedy Institute Of Rheumatology	TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
US5409886A (en) *	1993-02-18	1995-04-25	Mitsui Toatsu Chemicals, Incorporated	3-pyrroline-2-one derivatives and herbicidal compositions containing same
US6171585B1 (en)	1993-05-14	2001-01-09	Cedars-Sinai Medical Center	IVIg immunosuppression in HLA-sensitized transplant recipients
US20020068057A1 (en) *	1994-03-10	2002-06-06	Marc Feldmann	Treatment of autoimmune and inflammatory disorders
US5578609A (en) *	1994-03-25	1996-11-26	The Dupont Merck Pharmaceutical Company	2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
US5627193A (en) *	1995-02-09	1997-05-06	Mitsui Toatsu Chemicals, Inc.	Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds
WO1997042953A1 (en) *	1996-05-10	1997-11-20	Novartis Ag	Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation
US6207679B1 (en)	1997-06-19	2001-03-27	Sepracor, Inc.	Antimicrobial agents uses and compositions related thereto
US6376670B1 (en)	1997-06-19	2002-04-23	Sepracor Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6103905A (en) *	1997-06-19	2000-08-15	Sepracor, Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
AU757059B2 (en)	1997-06-19	2003-01-30	Sepracor, Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
UA65587C2 (en)	1997-10-09	2004-04-15	Baker Norton Pharma	Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
WO1999038846A1 (en) *	1998-01-30	1999-08-05	Procept, Inc.	Immunosuppressive agents
TW581681B (en) *	1998-02-20	2004-04-01	Nektar Therapeutics	Liquid crystal forms of cyclosporin
KR100312454B1 (ko) *	1998-03-27	2001-11-14	김용규	토토마이세틴을 생산하는 스트렙토마이세스 속 미생물 및 그로부터 생산된 토토마이세틴을 유효성분으로 함유하는 면역억제제
US7323471B1 (en) *	1999-08-13	2008-01-29	Dor Biopharma, Inc.	Topical azathioprine for the treatment of oral autoimmune diseases
US20160287549A1 (en)	2013-11-22	2016-10-06	Genzyme Corporation	Novel methods for treating neurodegenerative diseases
MX378664B (es) *	2014-02-07	2025-03-10	Neurocrine Biosciences Inc	Composiciones farmaceuticas que comprenden un farmaco antipsicotico y un inhibidor de la isoforma 2 del transportador de monomina vesicular (vmat2) y sus usos.
WO2015120436A2 (en) *	2014-02-10	2015-08-13	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Stat3 phosphorylation during graft-versus-host disease
LT3368534T (lt)	2015-10-30	2021-04-12	Neurocrine Biosciences, Inc.	Valbenazino ditozilatas ir jo polimorfai
PT3394057T (pt)	2015-12-23	2022-04-21	Neurocrine Biosciences Inc	Método sintético para a preparação de 2-amino-3-metilbutanoato de di(4-metilbenzenesulfonato) (s)-(2r,3r,11br)-3-isobutil-9,10-dimetoxi-2,3,4,6,7,11bhexaidro-1h-pirido[2,1,-a]lsoquinolin-2-ilo
US20200093808A1 (en)	2017-01-27	2020-03-26	Neurocrine Biosciences, Inc.	Methods for the Administration of Certain VMAT2 Inhibitors
MA50175B1 (fr)	2017-09-21	2025-05-30	Neurocrine Biosciences, Inc.	Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
WO2019074492A1 (en)	2017-10-10	2019-04-18	Obrien Christopher F	METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
KR20250070134A (ko)	2017-10-10	2025-05-20	뉴로크린 바이오사이언시즈 인코퍼레이티드	특정 vmat2 억제제의 투여 방법
SG11202100303QA (en)	2018-08-15	2021-02-25	Neurocrine Biosciences Inc	Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en)	2019-08-23	2021-03-09	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR6592M (de) *	1967-10-31	1968-12-30
GB1334705A (en) *	1970-06-19	1973-10-24	Ici Ltd	Pharmaceutical compositions containing kynurenic acid derivatives
CH576445A5 (de) *	1972-03-10	1976-06-15	Ciba Geigy Ag
DE2449030A1 (de) *	1974-10-11	1976-05-20	Schering Ag	Neue pyridin-derivate
US4407803A (en) *	1981-08-17	1983-10-04	Abbott Laboratories	Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives
US4680299A (en) *	1984-04-30	1987-07-14	E.I. Du Pont De Nemours And Company	2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
FI75308C (sv) *	1985-01-25	1988-06-09	Ky Carlson Project Kb	Hydrostatiskt drivsystem.
US4625034A (en) *	1985-02-04	1986-11-25	Usv Pharmaceutical Corp.	1,2-Dihydro; 1,2,3,4-tetrahydro; 5,8 dihydro; and 5,6,7,8-tetrahydroquinoline derivatives
US4661499A (en) *	1985-06-18	1987-04-28	Merck Frosst Canada, Inc.	2-[(substituted)-phenoxymethyl]quinolines
GB8602372D0 (en) *	1986-01-31	1986-03-05	Sandoz Ltd	Organic compounds
US4851409A (en) *	1986-02-14	1989-07-25	Merck Frosst Canada Inc.	2-substituted quinoline dioic acids and pharmaceutical compositions
US4847381A (en) *	1987-08-31	1989-07-11	American Cyanamid Company	2-Phenyl-4-quinoline carboxylic acids
US4968701A (en) *	1988-04-26	1990-11-06	E. I. Du Pont De Nemours And Company	4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
US4861783A (en) *	1988-04-26	1989-08-29	E. I. Du Pont De Nemours And Company	4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases
DE3814504A1 (de) *	1988-04-29	1989-11-09	Bayer Ag	(alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln

1990
- 1990-06-11 US US07/535,672 patent/US5204329A/en not_active Expired - Fee Related
1991
- 1991-06-05 ES ES91910880T patent/ES2114888T3/es not_active Expired - Lifetime
- 1991-06-05 AU AU80873/91A patent/AU664354B2/en not_active Ceased
- 1991-06-05 CA CA002085002A patent/CA2085002A1/en not_active Abandoned
- 1991-06-05 DE DE69129332T patent/DE69129332T2/de not_active Expired - Fee Related
- 1991-06-05 AT AT91910880T patent/ATE165511T1/de not_active IP Right Cessation
- 1991-06-05 JP JP91510655A patent/JPH05507697A/ja active Pending
- 1991-06-05 KR KR1019920703177A patent/KR930700107A/ko not_active Ceased
- 1991-06-05 DK DK91910880T patent/DK0537191T3/da active
- 1991-06-05 WO PCT/US1991/003788 patent/WO1991019498A1/en not_active Ceased
- 1991-06-05 EP EP91910880A patent/EP0537191B1/de not_active Expired - Lifetime
- 1991-06-10 IL IL9842591A patent/IL98425A/en not_active IP Right Cessation
- 1991-06-10 IE IE196291A patent/IE911962A1/en unknown
- 1991-06-11 ZA ZA914456A patent/ZA914456B/xx unknown

Also Published As

Publication number	Publication date
EP0537191B1 (de)	1998-04-29
JPH05507697A (ja)	1993-11-04
IE911962A1 (en)	1991-12-18
AU664354B2 (en)	1995-11-16
CA2085002A1 (en)	1991-12-12
AU8087391A (en)	1992-01-07
ES2114888T3 (es)	1998-06-16
DE69129332D1 (de)	1998-06-04
US5204329A (en)	1993-04-20
WO1991019498A1 (en)	1991-12-26
DE69129332T2 (de)	1998-08-27
ZA914456B (en)	1993-02-24
EP0537191A1 (de)	1993-04-21
DK0537191T3 (da)	1998-10-07
EP0537191A4 (en)	1993-08-11
KR930700107A (ko)	1993-03-13
IL98425A (en)	1995-06-29

Legal Events

Date	Code	Title	Description
1998-11-15	UEP	Publication of translation of european patent specification
2000-03-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE165511T1 (de)	1998-05-15	Behandlung von organtransplantatsabstossung
ES2099158T3 (es)	1997-05-16	Tratamiento del rechazo de trasplantes o de enfermedades autoinmunitarias y complejo de la formula general x-pro-y-boropro asociada al mismo.
DK0484281T4 (da)	2001-02-05	Cyclosporiner
NO961345L (no)	1996-06-03	O-aryl, O-alkyl-, O-alkenyl- og O-alkynylmakrolider med immunundertrykkende aktivitet
DE59905954D1 (de)	2003-07-17	Dialkylfumarate zur behandlung von autoimmunerkrankungen
ATE211467T1 (de)	2002-01-15	4-amino-derivate der mycophenolsäure mit immun suppressiver wirkung
DE69109560D1 (de)	1995-06-14	Fungizide Zusammensetzung zur Behandlung von Saatgut.
DE69435303D1 (de)	2010-09-02	Er behandlung von krankheiten bei denen eine cytok
ATE250625T1 (de)	2003-10-15	IM WESENTLICHEN REINES ZONULIN ALS PHYSIOLOGISCHER MODULATOR VON ßTIGHT JUNCTIONSß BEI SÄUGERN
FI913142A0 (fi)	1991-06-27	Migraenfoerhindrande alkoxipyrimidinderivat.
MY106038A (en)	1994-03-31	4-quinoline carboxylic acid derivatives useful as immunosuppressive agents.
FI931204A0 (fi)	1993-03-18	Nya, saosom lipooxigenasinhibitorer verkande aminobensosultamderivat
BG93298A (bg)	1993-12-24	Имуностимулиращи 6-арил-5,6-дихидроимидазо(2,1-в)тиазолови производни
DE3875306D1 (de)	1992-11-19	Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
CA2060474A1 (en)	1993-07-28	Pharmaceutical use
DE69125940D1 (de)	1997-06-05	Pharmazeutische zusammensetzungen die 5-difluormethoxy-2-[3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten
DE60045638D1 (de)	2011-03-31	Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
ATE210126T1 (de)	2001-12-15	4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
DK0468258T3 (da)	1996-02-26	Substituerede pyridooxaziner
EA199900363A1 (ru)	1999-12-29	Новые производные пентаэритрита, их получение и применение, а также промежуточные продукты для их синтеза
RU97117419A (ru)	1999-08-10	Эндопротез голеностопного сустава
DE59101882D1 (de)	1994-07-14	Inhibitor der proliferation von endothelzellen.
EP0653208A3 (de)	1995-10-11	Substanz P Antagonisten zur Behandlung oder Verhütung des sonnenbrandes.
DE59102569D1 (de)	1994-09-22	Sulfierte hydroxycarbonsäureester.
FR2669539B1 (fr)	1996-08-23	Dispositif pour la circulation artificielle du sang et transfuseur autologue de sang total.